Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,020 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urological Diseases Clear all
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

NCT03097016
View directory record Official record
Conditions
Renal Insufficiency
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

NCT00523640
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
combination of gemcitabine, capecitabine, and bevacizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions
PF-06940434, PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

NCT01974817
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
13-valent conjugate pneumococcal vaccine
Biological
Lead sponsor
Michigan State University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Precise Transvaginal Tape Placement Trial

NCT02101489
View directory record Official record
Conditions
Stress Urinary Incontinence, Urinary Incontinence
Interventions
Foley Catheter
Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy

NCT02189291
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Tract Infections, Urinary Retention
Interventions
Immediate catheter removal, Post op day 1 catheter removal
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT03160274
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
Interventions
Genetic screening
Genetic
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167
View directory record Official record
Conditions
End Stage Renal Disease, Infection
Interventions
Intravenous antibiotics
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Integrating Conservative Kidney Management Options and Advance Care Planning Into a Pre-Dialysis Educational Program

NCT03229811
View directory record Official record
Conditions
Advance Care Planning, Chronic Kidney Diseases, Conservative Kidney Management
Interventions
ESRD education + conservative kidney management and ACP education
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib for Advanced Urothelial Cancer

NCT01688999
View directory record Official record
Conditions
Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
Interventions
Cabozantinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 11, 2026, 8:23 AM EDT
Enrolling by invitation Not applicable Interventional

Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy

NCT07046832
View directory record Official record
Conditions
Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma, Biopsy
Interventions
Augmented Reality Guided Biopsy, Ultrasound Guided Biopsy
Device
Lead sponsor
MediView XR, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational

Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

NCT02083133
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Renal Dysfunction, Insulin Dosing
Interventions
Not listed
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 99 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

NCT00937833
View directory record Official record
Conditions
Urinary Incontinence, Prostate Cancer
Interventions
Prostatectomy, Surgisis Male Sling
Procedure · Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

NCT00835978
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
31
States / cities
Antioch, California • Bakersfield, California • Pleasant Hill, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

NCT04080076
View directory record Official record
Conditions
Renal Disease
Interventions
Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
65 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lawrenceville, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Treatment for Systemic Lupus Erythematosus

NCT00046774
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
MRA 003 US
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Enrolling by invitation Not applicable Interventional

Heterozygous Individuals for AGXT and Kidney Stones

NCT04430426
View directory record Official record
Conditions
Kidney Stone, Urolithiasis, Calcium Oxalate
Interventions
Controlled Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

NCT00923390
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer
Interventions
2G-1 TCR Retroviral Vector-Transduced lyn, Aldesleukin, Cyclophosphamide, Fludarabine, (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Genetic · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Body and Room Temperature Saline in Urodynamics

NCT00355433
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Urodymanics
Procedure
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
TAMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 11, 2026, 8:23 AM EDT
Not yet recruiting Phase 1 Interventional

Anti-Interleukin-6 (IL6) in Calciphylaxis

NCT07708038
View directory record Official record
Conditions
Calciphylaxis
Interventions
Tocilizumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 8:23 AM EDT